Omeros (FRA:3O8) Marketable Securities : €151.07 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Omeros's Marketable Securities for the quarter that ended in Dec. 2023 was €151.07 Mil.

Omeros's annual Marketable Securities increased from Dec. 2021 (€49.97 Mil) to Dec. 2022 (€173.61 Mil) but then declined from Dec. 2022 (€173.61 Mil) to Dec. 2023 (€151.07 Mil).

Omeros Marketable Securities Historical Data

The historical data trend for Omeros's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Marketable Securities Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

51.93

102.30

49.97

173.61

151.07

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Marketable Securities	Get a 7-Day Free Trial															173.61	343.27	308.91	262.05	151.07

Omeros Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Omeros (FRA:3O8) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Omeros Marketable Securities Related Terms

Thank you for viewing the detailed overview of Omeros's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines